摘要
Background： Helicohacterpylori （H. pylori） frequently colonizes the stomach. Gastroesophageal reflux disease （GERD） is a common and costly disease. But the relationship ofH. pylori and GERD is still unclear. This study aimed to explore the effect ofH. p.vlori and its eradication on reflux esophagitis therapy. Methods： Patients diagnosed with reflux esophagitis by endoscopy were enrolled; based on rapid urease test and Warth-Starry stain, they were divided into H. pylori positive and negative groups. H. pylori positive patients were randomly given H. pylori eradication treatment for 10 days, then esomeprazole 20 mg bid for 46 days. The other patients received esomeprazole 20 mg bid therapy for 8 weeks. After treatment, three patient groups were obtained： H. pylori positive eradicated, H. pylori positive uneradicated, and H. pylori negative. Before and after therapy, reflux symptoms were scored and compared. Healing rates were compared among groups. The x2 test and t-test were used, respectively, for enumeration and measurement data. Results： There were 176 H. pylori positive （with 92 eradication cases） and 180 negative cases. Healing rates in the H. pylori positive eradicated and H. pylori positive uneradicated groups reached 80.4% and 79.8% （P = 0.911）, with reflux symptom scores of 0.22 and 0.14 （P = 0.588）. Healing rates of esophagitis in the 14. pylori positive uneradicated and H. pylori negative groups were, respectively, 79.8% and 82.2% （P = 0.848）; reflux symptom scores were 0.14 and 0.21 （P = 0.546）. Conclusions： Based on esomeprazole therapy, H. pylori infection and eradication have no significant effect on reflux esophagitis therapy.
Background： Helicohacterpylori （H. pylori） frequently colonizes the stomach. Gastroesophageal reflux disease （GERD） is a common and costly disease. But the relationship ofH. pylori and GERD is still unclear. This study aimed to explore the effect ofH. p.vlori and its eradication on reflux esophagitis therapy. Methods： Patients diagnosed with reflux esophagitis by endoscopy were enrolled; based on rapid urease test and Warth-Starry stain, they were divided into H. pylori positive and negative groups. H. pylori positive patients were randomly given H. pylori eradication treatment for 10 days, then esomeprazole 20 mg bid for 46 days. The other patients received esomeprazole 20 mg bid therapy for 8 weeks. After treatment, three patient groups were obtained： H. pylori positive eradicated, H. pylori positive uneradicated, and H. pylori negative. Before and after therapy, reflux symptoms were scored and compared. Healing rates were compared among groups. The x2 test and t-test were used, respectively, for enumeration and measurement data. Results： There were 176 H. pylori positive （with 92 eradication cases） and 180 negative cases. Healing rates in the H. pylori positive eradicated and H. pylori positive uneradicated groups reached 80.4% and 79.8% （P = 0.911）, with reflux symptom scores of 0.22 and 0.14 （P = 0.588）. Healing rates of esophagitis in the 14. pylori positive uneradicated and H. pylori negative groups were, respectively, 79.8% and 82.2% （P = 0.848）; reflux symptom scores were 0.14 and 0.21 （P = 0.546）. Conclusions： Based on esomeprazole therapy, H. pylori infection and eradication have no significant effect on reflux esophagitis therapy.
